Difference between revisions of "Ublituximab (Briumvi)"
m (Jwarner moved page Ublituximab (TG-1101) to Ublituximab (Briumvi): FDA approval) |
m |
||
Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=670500 NCI Drug Dictionary]: A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=670500 NCI Drug Dictionary]: A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells. | ||
− | == | + | ==Diseases for which it is used== |
− | + | *[[Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL)|CLL]] | |
− | |||
− | |||
− | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== |
Latest revision as of 01:28, 13 January 2024
Mechanism of action
From the NCI Drug Dictionary: A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells.
Diseases for which it is used
History of changes in FDA indication
No antineoplastic indication, at this time.
- 2023-01-06: Approved for the treatment of relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Also known as
- Code names: LFB-R603, TG-20, TG-1101, TGTX-1101
- Generic name: ublituximab-xiiy
- Brand name: Briumvi